Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16991664 | 0.88 | CHEK1 (0.48) | ACLYCTSAPDE4AMMP3MMP2 | |
| SCHEMBL3996717 | 0.88 | CFD (0.51) | ACLYCTSAL3MBTL1ARMMP2 | |
| SCHEMBL30468153 | 0.87 | AR (0.50) | PDE4AL3MBTL1ARALDH1A1MAPT | |
| SCHEMBL20855586 | 0.87 | AR (0.50) | PDE4AL3MBTL1ARALDH1A1MAPT | |
| SCHEMBL24302512 | 0.81 | NR1H4 (0.58) | ACLYPDE4AL3MBTL1MAPTMEN1 | |
| SCHEMBL6099384 | 0.80 | ALDH1A1 (0.46) | ACLYCTSAPDE4AL3MBTL1ALDH1A1 | |
| SCHEMBL22801048 | 0.78 | KIF11 (0.47) | ACLYMMP3MMP2ALDH1A1MAPT | |
| SCHEMBL7291041 | 0.78 | AR (0.46) | PDE4AARALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14525311 | 0.76 | HSD17B1 (0.42) | MMP3MMP2ALDH1A1MAPT | |
| SCHEMBL13802320 | 0.76 | AR (0.50) | ACLYCTSAARMMP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | NATIONAL INSTITUTES OF HEALTH | 2020-12-24 | — | — | US | disclosed |
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | ACLY 3547/4885CTSA 891/4885PDE4A 2214/4885 |
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | MAVS, ZC3HAV1, EIF2AK2 | ACLY 2681/4885CTSA 2324/4885PDE4A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.